UA35656C2 - Method for treating continuously progressive psychic diseases leading to dementia - Google Patents
Method for treating continuously progressive psychic diseases leading to dementiaInfo
- Publication number
- UA35656C2 UA35656C2 UA99127123A UA99127123A UA35656C2 UA 35656 C2 UA35656 C2 UA 35656C2 UA 99127123 A UA99127123 A UA 99127123A UA 99127123 A UA99127123 A UA 99127123A UA 35656 C2 UA35656 C2 UA 35656C2
- Authority
- UA
- Ukraine
- Prior art keywords
- dementia
- diseases leading
- continuously progressive
- treating
- psychic diseases
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the medicine, namely to psychoneurology and may be used for treating the continuously progressive psychic diseases leading to dementia such as schizophrenia, Alzheimer disease, the senile dementia of Alzheimer-like type, Niemann-Pick disease etc. The method for treating the continuously progressive psychic diseases leading to dementia comprises the intravenous and/or intramuscular administration of blood plasma that is selected on the genetic basis. The duration of the treatment depends on the time required for the stable elimination of the pathology and the recovery of the lost abilities.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA99127123A UA35656C2 (en) | 1999-12-27 | 1999-12-27 | Method for treating continuously progressive psychic diseases leading to dementia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA99127123A UA35656C2 (en) | 1999-12-27 | 1999-12-27 | Method for treating continuously progressive psychic diseases leading to dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
UA35656C2 true UA35656C2 (en) | 2001-04-16 |
Family
ID=74181655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA99127123A UA35656C2 (en) | 1999-12-27 | 1999-12-27 | Method for treating continuously progressive psychic diseases leading to dementia |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA35656C2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10245285B2 (en) | 2016-04-28 | 2019-04-02 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
US10357513B2 (en) | 2017-04-26 | 2019-07-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US10617744B2 (en) | 2015-06-15 | 2020-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
US10688154B2 (en) | 2011-04-08 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US10688130B2 (en) | 2013-12-09 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
US11103530B2 (en) | 2018-10-26 | 2021-08-31 | Alkahest, Inc. | Methods of improving or accelerating postoperative recovery |
US11236340B2 (en) | 2010-01-28 | 2022-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) |
-
1999
- 1999-12-27 UA UA99127123A patent/UA35656C2/en unknown
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11912998B2 (en) | 2010-01-28 | 2024-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating aging-associated cognitive impairment by reducing CCR3 |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US11236340B2 (en) | 2010-01-28 | 2022-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) |
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
US10688154B2 (en) | 2011-04-08 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
US10688130B2 (en) | 2013-12-09 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US11141469B2 (en) | 2015-06-15 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10617744B2 (en) | 2015-06-15 | 2020-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10245285B2 (en) | 2016-04-28 | 2019-04-02 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
US10905717B2 (en) | 2016-04-28 | 2021-02-02 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
US10874692B2 (en) | 2017-04-26 | 2020-12-29 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
US11413308B2 (en) | 2017-04-26 | 2022-08-16 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
US10357513B2 (en) | 2017-04-26 | 2019-07-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
US11103530B2 (en) | 2018-10-26 | 2021-08-31 | Alkahest, Inc. | Methods of improving or accelerating postoperative recovery |
US11298377B2 (en) | 2018-10-26 | 2022-04-12 | Alkahest, Inc. | Methods of improving wound healing |
US11547724B2 (en) | 2018-10-26 | 2023-01-10 | Alkahest, Inc. | Methods of treating a subject for pain |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT74004A (en) | Inhibitors of beta-amyloid protein production | |
WO2004000387A3 (en) | Dialysis system for treatment of vulnerable patients and methods of use | |
WO2005065383A3 (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
DE60317562D1 (en) | BENZOFURANDERIVATE, METHOD FOR THE PRODUCTION AND INTERMEDIATE PRODUCTS THEREOF | |
UA35656C2 (en) | Method for treating continuously progressive psychic diseases leading to dementia | |
HK1087398A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
MY135838A (en) | Methods for the treatment of mental disorders | |
ATE435026T1 (en) | METHOD FOR PREVENTION AND TREATMENT OF DIABETES USING NEURTURIN | |
MXPA03009849A (en) | Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases. | |
HU213677B (en) | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them | |
UA27102C2 (en) | Composition for stabilization of blood plasma in the process of pasteurization, method of plasma pasteurization and drug for therapy by plasma medication | |
GB0020504D0 (en) | Therapeutic method | |
DE60032590D1 (en) | METHOD FOR TREATING SCHIZOPHRENIA | |
TW200510437A (en) | Phosphinane compound with immunomodulating activity | |
ATE285773T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
DE3787437D1 (en) | SIALOSYL CHOLESTEROL, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM. | |
DK82892D0 (en) | APPLICATION OF BRAIN ADDITION FROM BEES AND WHEPS FOR THE PREPARATION OF MEDICINAL PRODUCTS TO TREAT INFECTIONS | |
HUP0103660A2 (en) | Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid | |
WO2002017917A8 (en) | Manzamines for treatment of drug resistant infection | |
IL117083A0 (en) | Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical agents containing these compounds | |
WO2006041838A3 (en) | Heparinoid compositions for treatment and prevention of dementia | |
AU2396900A (en) | Treatment and prevention of hiv and other viral infections | |
UA29106A (en) | The method for treatment of vibration disease | |
WO2003066806A3 (en) | Therapeutic use of aziridino compounds | |
IL165996A0 (en) | Novel thiophene acyl hydrazino derivatives method for preparing same use thereof as medicines pharmaceutical compositions and novel use |